Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Hauschild Discusses the Dabrafenib BREAK-3 Trial

June 26th 2012

Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.

Mutations Pass From Primary to Recurrent Endometrial Cancer

June 26th 2012

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

Unexpected Mutations Doom Therapy for Glioblastoma

June 25th 2012

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

Dr. Sandler Discusses the Tivantinib Mechanism of Action

June 25th 2012

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors

June 25th 2012

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

Dr. Gandara on TS Expression in ALK-Positive NSCLC

June 19th 2012

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Kris Discusses ASCO 2012 Lung Cancer Information

June 18th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Time Management: Balancing Clinical Education With Scientific Research

June 15th 2012

With careful attention to detail and conscientious efforts, clinical skills are likely to be transferable from clinical education to meeting research goals.

On the Horizon: Novel Inhibitors for Hematologic Malignancies

June 13th 2012

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

JAK Pathway Yielding Results

June 13th 2012

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Adjei on the Need for Targeted Therapy Education

June 12th 2012

Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education

IPCC Case-Based Discussion: How Should We Sequence Therapy?

June 12th 2012

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.

Grappling With the Genome: Cancer Centers Approach Puzzle in Different Ways

June 11th 2012

As the cost of sequencing and analyzing genetic data continues to fall, the nation's leading cancer centers keep unveiling ambitious new clinical programs and research projects that will change the way every cancer specialist practices.

University of Michigan Comprehensive Cancer Center: Leading the Way in Targeted Therapies Cancer Care

June 7th 2012

The U-M Comprehensive Cancer Center in Ann Arbor offers diagnostic, treatment, and support services while serving as a model for other branches of the U-M Health System and for academic peer organizations nationwide.

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

CDX-011 Shows Promise in GPNMB-Positive Triple-Negative Breast Cancer

May 23rd 2012

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Dr. Chapman on BRAF/MEK Combination for Melanoma

May 16th 2012

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

May 16th 2012

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL